Exercise training increases anabolic and attenuate catabolic and apoptotic processes in aged skeletal muscle of male rats

Mohammad Mosaferi Ziaaldini¹, Erika Koltai¹, Zsolt Csende², Sataro Goto³, Istvan Boldogh⁴, Albert W. Taylor⁵, Zsolt Radak¹

¹Research Institute of Sport Science, Semmelweis University, Budapest, Hungary Department of Biomechanics, Semmelweis University, Budapest, ³Department of Exercise Physiology, School of Health and Sport Science, Juntendo University, Chiba, Japan, ⁴Department of Microbiology and Immunology, Sealy Center for Molecular Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas 77555, USA, ⁵Faculty of Health Sciences, The University of Western Ontario, London, Ontario, Canada

Correspondence: Zsolt Radak, Ph.D., DSc
Institute of Sport Science
Faculty of Physical Education and Sport Science
Semmelweis University
Alkotas u. 44.TF Budapest, Hungary
Tel: +36 1 3565764, Fax: +36 1 356 6337
Email: radak@tf.hu
Abstract

Aging results in significant loss of mass and function of skeletal muscle, which negatively impacts the quality of life. In this study we investigated whether aerobic exercise training has the potential to alter anabolic and catabolic pathways in skeletal muscle. Five and twenty eight month old rats were used in the study. Aging resulted in decreased levels of follistatin/mTOR/Akt/Erk activation and increased myostatin/Murf1/2, proteasome subunits, and protein ubiquitination levels. In addition, TNF-α, reactive oxygen species (ROS), p53, and Bax levels were increased while Bcl-2 levels were decreased in skeletal muscle of aged rats. Six weeks of exercise training at 60% of VO2max reversed the age-associated activation of catabolic and apoptotic pathways and increased anabolic signaling. The results suggest that the age-associated loss of muscle mass and cachexia could be due to orchestrated down-regulation of anabolic and up-regulation of catabolic and pro-apoptotic processes. These metabolic changes can be attenuated by exercise training.
Introduction

Skeletal muscle is crucial for movement and also plays an important role in sugar and fat metabolism, and immune response. Age-associated loss in function and mass of skeletal muscle is well documented (Bijlsma and others 2012; Reid and Fielding 2012). However, the causative mechanism(s) controlling this complex process is not well understood. Enhanced generation of inflammation (Degens 2010), aging-related increases in the level of reactive oxygen species (ROS) (Hiona and Leeuwenburgh 2008), altered metabolism (Lawler and Hindle 2011), and increased rates of protein degradation (Witt and others 2008) are also on the list of potential causative factors of sarcopenia. Indeed, it has been reported that administration of exogenous tumor necrosis factor alpha (TNF-α) leads to a significant decrease in the mass of skeletal muscle (Llovera and others 1993). This cytokine can interfere with the contractile properties of skeletal muscle causing decreased force generating capacity (Reid and others 2002). Inflammation can readily increase the concentration of ROS, which above certain levels jeopardizes cellular function (Ji 2007; Langen and others 2003; Radak and others 2005). Recently it has been reported that myostatin, which is a negative regulator of muscle growth and is induced in aged skeletal muscle (Bowser and others 2013; Brioche and others 2013), can also add to higher levels of ROS (Sriram and others 2011). Increased levels of myostatin can readily reduce protein synthesis (Hitachi and others 2014) and it appears that the rate of protein degradation is enhanced in aged skeletal muscle (Goto and others 2007). It has also been shown that the ubiquitin-dependent proteasome system can be activated with aging (Radak and others 2002), and recent information indicates that muscle RING finger 1/2 (Murf1/2), which is an ubiquitin ligase, could have an important role in aging skeletal muscle (Sacheck and others 2007). Thus, it is obvious that the mechanism(s) affecting muscular atrophy is very complex and extremely complicated.

Physical exercise has been shown to retard age-associated loss of muscle mass (Dickinson and others 2013), and supplementation of growth hormone (Brioche and others 2013; Nass 2013).

Therefore the aim of the present study was to obtain a picture of the signaling anabolic, catabolic and apoptotic pathways of aged skeletal muscle. The role of aerobic exercise training on these pathways was investigated.
Methods

Animals and training protocol
Twelve young (three months old) and twelve eight month old male Wistar rats were used in the study and grouped into young control (YC), young exercised (YE), old control (OC), old exercised (OE).

The investigation was carried out according to the requirements of The Guiding Principles for Care and Use of Animals, EU, and approved by the local ethics committee. Exercised rats were introduced to treadmill running for three days; then for the next two weeks the running speed was set at 10 m/min, with a 5% incline for 30 min/day. The running speed and duration of the exercise were gradually increased to 60% of VO2max of the animals. As a result, by the final week of the six weeks training program, young animals ran at 22 m/min, on a 10% incline, for 60 min, whereas old animals ran at 13 m/min, and a 10% incline for 60 min.

At the end of the study, the rats were anaesthetized with intraperitoneal injections of ketamine (50 mg/kg) and perfused by 4% paraformaldehyde in phosphate buffered saline (PBS, pH 7.4). This procedure was carried out two days after the last exercise session to avoid the metabolic effects of the final run.

Quadriceps muscle was carefully excised and homogenized in buffer containing 137 mMNaCl, 20mM Tris-HCl pH 8.0, 2% NP 40, 10% glycerol and protease inhibitors. The protein content was measured by the Bradford method using BSA as a standard, and the samples were stored at -80°C.

Estimation of Oxidant levels and Redox Active Iron
Intracellular oxidant and redox-active iron levels (Kalyanaraman and others 2011)) were estimated using modifications of the dichlorodihydrofluoresceindiacetate (H₂DCFDA) staining method (Radak and others 2004). In brief, the H₂DCFDA (Invitrogen-Molecular Probes #D399) was dissolved to a concentration of 12.5 mM in ethanol and kept at -80°C in the dark. The solution was freshly diluted with potassium phosphate buffer to 125 μM before use. For fluorescence reactions, 96-well, black microplates were loaded with potassium phosphate buffer (pH 7.4) to a final concentration of 152 μM/well. Then 8 μl diluted tissue homogenate and 40 μl 125 μM dye were added to achieve a final dye concentration of 25 μM. The change in fluorescence intensity was monitored every five
minutes for 30 minutes with excitation and emission wavelengths set at 485 nm and 538 nm (Fluoroskan Ascent FL). The fluorescence intensity unit was normalized with the protein content and expressed in relative unit production per minute.

Western blots

Ten to 50 micrograms of protein were electrophoresed on 8-12% v/v polyacrylamide SDS-PAGE gels. Proteins were electrotransferred onto PVDF membranes. The membranes were subsequently blocked and after blocking, PVDF membranes were incubated at room temperature with antibodies (1:500 #sc-6884 Santa CruzGDF-8/11(C-20); 1:500 #sc-30194 Santa Cruz Follistatin (H-114); 1:500 #sc-32920 Santa Cruz MuRF1(H-145); 1:500 #sc-49457 Santa Cruz MuRF2(N-15); 1:1000 #9272s cell signaling Akt; 1:1000 #9271s cell signaling Phospho-Akt (Ser473); 1:500 #sc-8319 Santa Cruz mTOR (H-266); 1:1000 #5536 cell signaling Phospho-mTOR (Ser2448); 1:1000 #9102 cell signaling p44/42 MAPK (Erk1/2); 1:1000 #9106 cell signaling Phospho-p44/42 MAPK (Erk1/2)(Thr202/Tyr204); 1:500 #sc-1350 Santa Cruz TNFa(N-19); 1:500 #sc-526 Santa Cruz Bax (P-19); 1:500 #sc-492 Santa Cruz Bcl-2 (N-19); 1:500 #sc-1311 Santa Cruz p53 (C-19); 1:1000 #2459 cell signaling PSMA6; 1:1000 #3936 cell signaling Ubiquitin (P4D1); 1:500 #sc-15404 Santa Cruz SIRT1 (H-300); 1:500 #sc-69359 Santa Cruz COX4 (D-20); 1:500 #sc-7159 Santa Cruz cytochrome c (H-104); 1:2000 #sc-81178 Santa Cruz β-Actin (ACTBD11B7). After incubation with primary antibodies, membranes were washed in TBS-Tween-20 and incubated with HRP-conjugated secondary antibodies. After incubation with the secondary antibody, membranes were repeatedly washed. Membranes were incubated with chemiluminescent substrate (Thermo Scientific, SuperSignal West Pico Chemiluminescent Substrate #34080) and protein bands were visualized on X-ray films. The bands were quantified by ImageJ software, and normalized to β-actin, which served as an internal control.

Statistical analyses

Statistical significance was assessed by Kruskal-Wallis ANOVA followed by Mann-Whitney U test in case of those variables where post-hoc analysis was adequate. The significance level was set at p < 0.05.
Results

The effects of aging

Aging resulted in significant decrease in the protein content of cytochrome C (Fig. 1A) and COX4 (Fig. 1B), indicating decreased mitochondrial content. The ROS levels were appraised using the H$_2$DCFDA staining method, and age-associated increase was detected (Fig. 2). Myostatin, which is a negative regulator of muscle growth significantly increased with aging (p<0.01) (Fig. 3A). An age-associated decrease in the follistatin levels, which is the antagonist of myostatin, was observed in OC group compared to YC (Fig. 3B). The ratio of pmTOR/mTOR, pAkt/Akt, did not change significantly as a result of aging (Fig. 3C,D). However the ratio of pERK/ERK increased in aged control group compared to young controls (Fig. 3E).

The assessment of protein degradation was made by measuring Murf1, Murf2, proteasome subunit alpha (PSMA6), and protein ubiquitination. Generally, all of these markers increased with aging (Fig. 4A-D). Degradation of proteins is associated with apoptosis and an increase in p53 levels was detected as a result of aging (Fig. 5A). Bax is a pro-apoptotic protein and an age-associated increase in this protein was found in the skeletal muscle (p<0.01) (Fig. 5B). TNF-α is an adipokine which can relate to apoptosis and it has been found unaltered with aging (Fig. 5C). Bax induces apoptosis by binding the Bcl-2 family, which was found to be significantly lower in aged muscle than in young muscle (Fig. 5D). SIRT1 is anti-apoptotic protein, which levels was not altered by aging (Fig. 5E).

The effects of exercise training

Six weeks running training at the intensity of 60% of VO2max resulted in an adaptive response in mitochondrial enzymes with significant elevation of cytochrome C levels in both young and aged groups. The training program eliminated the age-associated loss of cytochrome C (Fig. 1A) and COX4 (Fig. 1B). Exercise training did not significantly change the levels of ROS. Aerobic exercise training did not change the myostatin levels (Fig. 3A), however eliminated the age-associated increase. In accordance with this change, the follistatin levels increased by training in aged animals (Fig. 3B).
Exercise increased the pmTOR/mTOR levels in aged groups, while no statistical alteration was present in young groups, and this was true for pAkt/Akt ratio (Fig. 3C,D). However, exercise prevented the age related increase in the ratio pERK/ERK (Fig. 3E). Exercise training decreased the protein levels of Murf1 aged groups compared to aged control rats (Fig. 4A), while exercise decreased the levels of Murf2 in both age groups (Fig. 4B).

Interestingly statistical increase in PSMA6 and ubiquitination levels were found between young control and young exercise rats (Fig. 4.C,D), while in aged groups exercise does not significantly altered the levels of PSMA6 and protein ubiquitination. Exercise training did not result in significant alteration of p53, Bax, TNF-α and SIRT1 levels (Fig. 5.A,B,D,E), the only statistical difference in these apoptotic markers was that exercise decreased the Bcl2 levels in young group compared to young control rats (Fig. 5C).

Discussion

Age-associated loss in function and size of skeletal muscle leads to a decreased quality of life. The findings of the present study suggest that the loss of muscle mass is due to decreased activity of anabolic pathways and increased activity of catabolic pathways in skeletal muscle. The follistatin mediated anabolic pathway was found to be down-regulated in aged skeletal muscle. The IGF pathway is known to promote myogenesis (Rosen and others 1993), and follistatin mediated inhibition of myostatin causes enhanced expression of IGF-1(Gilson and others 2009) and activation of anabolic pathways, probably through an IGF-receptor (IGF-IR). Data from the present study demonstrate that aging results in down-regulation of follistatin mediated pathways. This is finding is in accordance with the observation, that administration of follistatin results in increased muscle protein synthesis (Suryawan and others 2006). Aerobic exercise has been shown to elevate serum levels of follistatin (Gorgens and others 2013), while exercise can activate Akt and Erk pathways (Boonsong and others 2007; Fuentes and others 2011; Pasiakos and others 2010; Williamson and others 2006), leading to enhanced production of follistatin (Chen and Ruiz-Echevarria 2013). In the present study we have observed that exercise could counter act with the effects of aging on follistatin levels, and this could be an important means by which regular exercise could attenuate sarcopenia.
The significant decrease in mass of skeletal muscle could be also due to the enhanced level of catabolic processes. Myostatin is a powerful negative regulator of muscle growth. Myostatin signaling results in activation of Smad2 and Smad3 and consequently the regulation of MyoD as well as the ubiquitin-associated degradation (Attisano and others 2001). This pathway is activated in aged skeletal muscle, suggesting the involvement of myostatin in age-associated muscle loss. Indeed, blockage of myostatin also curbs the activity of catabolic pathways (Thomas and Mitch 2013). On the other hand, cancer-associated cachexia has been shown to increase myostatin and Murf2 levels in skeletal muscle (Bonetto and others 2009). These data suggest a functional link between myostatin and Murf(s) mediated catabolism. Murf1 and Murf2 are ubiquitin ligases but results from work using Murf1 transgenic mice suggest that Murf1 can interfere with the ROS production of mitochondria in the cardiac muscle (Mattox and others 2014). Similar interaction could be present in the skeletal muscle. Murf1/Murf2 has been implicated in the remodeling of type-II fibers in skeletal muscle (Moriscot and others 2010) as these fibers lose more total area and function than type-I fibers during the aging process (Deschenes 2004; Pak and Aiken 2004). The increased level of Murf1/Murf2, hence, can be a compensatory mechanism to try to remodel these fibers, which includes degradation of damaged fibers. Aging resulted in increased levels of ROS, which are initiators/consequences of muscle wasting (Eley and others 2008) and closely related to the activation of apoptosis (Favier and others 2008). It has been reported that age-associated increases in p53 in skeletal muscle leads to mitochondrial release of cytochrome c and apoptosis (Tamilselvan and others 2007). In the present study aging resulted in increased levels of pro-apoptotic proteins p53 and Bax and down-regulation of anti-apoptotic Bcl-2 protein.

Exercise associated decrease in the levels of p53 and Bax in proteins could counteract the age-mediated pro-apoptotic pathways. SIRT1 is considered to be an anti-apoptotic protein (Radak and others 2013). However, an age-associated alteration of this protein was not observed, although exercise training increased the content of this protein in the older group. We have previously reported, using the same animals, that exercise increased the activity of SIRT1 (Koltai and others 2010). However, it is not clear if that finding affects the anti-apoptotic role of SIRT1. In addition, it has to be mentioned that the role of sirtuins in aging is very complex, sirtuins belong to the vitagen family together with heat shock proteins and thioredoxin (Calabrese and others 2011; Calabrese and others 2010; Calabrese and others 2012; Cornelius and others 2013). The U-shape dose response curve, which is often called
hormesis, is very representative to oxidants, oxidative damage and vitagens, and without question vitagens could play an important role in aging process (Calabrese and others 2007; Radak and others 2011). Nevertheless, the role of SIRT1 in age-associated loss of muscle mass needs further verification.

In conclusion, we report that aging results in significant decreases in anabolic processes of skeletal muscle by activation of the follistatin pathway. This finding, together with the data that show enhanced activation of myostatin, Murf1/2, PMSA6, protein ubiquitinating pathway, and apoptosis in skeletal muscle of aged animals, suggests that the age-associated loss in muscle mass is a result of altered protein synthesis and degradation. Exercise training, can reverse the decline in anabolic processes and increases in catabolic and apoptotic processes, and serve as an important tool to fight sarcopenia and cachexia.
Acknowledgement: This work was supported by Hungarian grant from OTKA (K 112810) awarded to Z. Radak.
References:


Bonetto, A.; Penna, F.; Minero, V.G.; Reffo, P.; Bonelli, G.; Baccino, F.M.; Costelli, P. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets. 9:608-616; 2009


Cornelius, C.; Perrotta, R.; Graziano, A.; Calabrese, E.J.; Calabrese, V. Stress responses, vitagenes and hormesis as critical determinants in aging and longevity: Mitochondria as a "chi". Immunity & ageing : I & A. 10:15; 2013


Favier, F.B.; Benoit, H.; Freyssenet, D. Cellular and molecular events controlling skeletal muscle mass in response to altered use. Pflugers Arch. 456:587-600; 2008

Fuentes, E.N.; Bjornsson, B.T.; Valdes, J.A.; Einarsdottir, I.E.; Lorca, B.; Alvarez, M.; Molina, A. IGF-I/PI3K/Akt and IGF-I/MAPK/ERK pathways in vivo in skeletal muscle are regulated by
nutrition and contribute to somatic growth in the fine flounder. Am J Physiol Regul Integr Comp Physiol. 300:R1532-1542; 2011


Hiona, A.; Leeuwenburgh, C. The role of mitochondrial DNA mutations in aging and sarcopenia: implications for the mitochondrial vicious cycle theory of aging. Exp Gerontol. 43:24-33; 2008


Kalyanaraman, B.; Darley-Usmar, V.; Davies, K.J.A.; Dennergy, P.; Forman, H.J.; Grisham, M.; Mann, G.; Moor; Roberts, J.J.F.; Ischiropoulos, H. The use of fluorescence probes to measure reactive oxygen and nitrogen species in cell: challenges, potentials and caveats. in press; 2011


Lawler, J.M.; Hindle, A. Living in a box or call of the wild? Revisiting lifetime inactivity and sarcopenia. Antioxid Redox Signal. 15:2529-2541; 2011


Mattox, T.A.; Young, M.E.; Rubel, C.E.; Spaniel, C.; Rodriguez, J.E.; Grevenkoed, T.J.; Gautel, M.; Xu, Z.; Anderson, E.J.; Willis, M.S. MuRF1 activity is present in cardiac mitochondria and regulates reactive oxygen species production in vivo. J Bioenerg Biomembr. 46:173-187; 2014


Radak, Z.; Chung, H.Y.; Naito, H.; Takahashi, R.; Jung, K.J.; Kim, H.J.; Goto, S. Age-associated increase in oxidative stress and nuclear factor kappaB activation are attenuated in rat liver by regular exercise. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 18:749-750; 2004


Radak, Z.; Zhao, Z.; Goto, S.; Koltai, E. Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA. Molecular aspects of medicine. 32:305-315; 2011


Figure legends

Fig. 1. The levels of cytochrome C and COX 4
Mitochondrial content was evaluated by cytochrome c and COX 4. Groups: YC, young control; YE, young exercised; YEI, young exercised IGF-1 treated, OC, old control; OE, old exercised, OEI, old exercised IGF-1 treated. Values are means ± SE for six animals per group. *p<0.05, **p<0.01.

Fig. 2. The evaluation of ROS content
The measurement of ROS levels was done by fluorescent detection of H2DCFDA. Groups: YC, young control; YE, young exercised; YEI, young exercised IGF-1 treated, OC, old control; OE, old exercised, OEI, old exercised IGF-1 treated. Values are means ± SE for six animals per group. *p<0.05, **p<0.01.

Fig. 3. Anabolic factors of skeletal muscle
Myostatin (A) and follistatin (B) levels were evaluated by Western blot. The activites of mTOR (C), Akt (D) ERK (E), were measured by the ratio of phosphorylated and total levels of mTOR, Akt and ERK. Groups: YC, young control; YE, young exercised; YEI, young exercised IGF-1 treated, OC, old control; OE, old exercised, OEI, old exercised IGF-1 treated. Values are means ± SE for six animals per group. *p<0.05, **p<0.01.

Fig. 4. Catabolic factors of skeletal muscle
MuRF1 (A) and MuRF2 (B) PSMA6 (C) and protein ubiquitination (D) levels were evaluated as markers of protein degradation. Groups: YC, young control; YE, young exercised; YEI, young exercised IGF-1 treated, OC, old control; OE, old exercised, OEI, old exercised IGF-1 treated. Values are means ± SE for six animals per group. *p<0.05, **p<0.01.

Fig. 5. Pro-apoptotic and anti-apoptotic markers in skeletal muscle
Pro-apoptotic factors p53 (A), BAX (B), and TNF-a (C) and anti-apoptotic factors Bcl-2 (D) and SIRT1 (E) were measured by immunoblot. Groups: YC, young control; YE, young exercised; YEI, young exercised IGF-1 treated, OC, old control;
OE, old exercised, OEI, old exercised IGF-1 treated. Values are means ± SE for six animals per group. *p<0.05, **p<0.01.
There is no conflict of interest regarding the manuscript
Fig 1.

A

Cytochorom C
B-actin

B

actin

15 KDa
43 KDa

17 KDa
43 KDa

B

Cox 4

B-actin

Relative density (unit)

YC YE OC OE

Relative density (unit)

YC YE OC OE
Fig 2.

ROS Levels

![Graph showing ROS Levels with YC, YE, OC, and OE categories.](image-url)
Fig 3.

A. Myostatin
- B-actin
  - 26 KDa
  - 43 KDa

B. Follistatin
- B-actin
  - 35 KDa

C. pmTOR
- mTOR
- 270 KDa

D. pAkt
- Akt
- 60 KDa

E. p-ERK 1
- p-ERK 2
- ERK 1
- ERK 2
- 44 KDa
- 42 KDa

Relative density (unit) vs. samples (YC, YE, OC, OE)
Fig 4.

A  
MuRF 1  B-actin
40 KDa

<table>
<thead>
<tr>
<th></th>
<th>YC</th>
<th>YE</th>
<th>OC</th>
<th>OE</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>0.6</td>
<td></td>
<td></td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>0.4</td>
<td></td>
<td></td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
<td></td>
<td>0.4</td>
<td></td>
</tr>
</tbody>
</table>

B  
MuRF 2  B-actin
60 KDa

<table>
<thead>
<tr>
<th></th>
<th>YC</th>
<th>YE</th>
<th>OC</th>
<th>OE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>0.6</td>
<td></td>
<td></td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>0.4</td>
<td></td>
<td></td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
<td></td>
<td>0.4</td>
<td></td>
</tr>
</tbody>
</table>

C  
PSMA6  B-actin
26 KDa

<table>
<thead>
<tr>
<th></th>
<th>YC</th>
<th>YE</th>
<th>OC</th>
<th>OE</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>0.6</td>
<td></td>
<td></td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>0.4</td>
<td></td>
<td></td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
<td></td>
<td>0.4</td>
<td></td>
</tr>
</tbody>
</table>

D  
Ubiquitin  B-actin
43 KDa

<table>
<thead>
<tr>
<th></th>
<th>YC</th>
<th>YE</th>
<th>OC</th>
<th>OE</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>0.6</td>
<td></td>
<td></td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>0.4</td>
<td></td>
<td></td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td></td>
<td></td>
<td>0.4</td>
<td></td>
</tr>
</tbody>
</table>